In accord with previous studies [28, 29], MCL1 inhibition showed modest activity (IC50 > 10 μM @ 1.5 h: ~50 nM @ 24 h), whereas BCLXL inhibition is known to be inactive on CLL [27, 30, 31]. Here, BCL2L1 is linked to B-cell chronic lymphocytic leukemia.